These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

98 related items for PubMed ID: 18825551

  • 1. Synthesis and preliminary screening of novel N-{2-[4-(substituted)piperazin-1-yl]-2-oxoethyl}acetamides as potential atypical antipsychotic agents.
    Chandra Sekhar KV, Rao VS, Krishna MM.
    J Enzyme Inhib Med Chem; 2009 Jun; 24(3):871-5. PubMed ID: 18825551
    [Abstract] [Full Text] [Related]

  • 2. Synthesis and preliminary pharmacological evaluation of N-2-(4-(4-(2-substitutedthiazol-4-yl) piperazin-1-yl)-2-oxoethyl)acetamides as novel atypical antipsychotic agents.
    Sekhar KV, Rao VS, Devambatla RKV, Kumar MM.
    Bioorg Med Chem Lett; 2008 Dec 01; 18(23):6054-7. PubMed ID: 18948000
    [Abstract] [Full Text] [Related]

  • 3. Design, synthesis, and preliminary in vitro and in vivo pharmacological evaluation of 2-{4-[4-(2,5-disubstituted thiazol-4-yl)phenylethyl]piperazin-1-yl}-1,8-naphthyridine-3-carbonitriles as atypical antipsychotic agents.
    Gowri Chandra Sekhar KV, Rao VS, Deuther-Conrad W, Reddy AS, Brust P, Krishna Kumar MM.
    J Enzyme Inhib Med Chem; 2011 Aug 01; 26(4):561-8. PubMed ID: 21171898
    [Abstract] [Full Text] [Related]

  • 4. Synthesis, computational studies and preliminary pharmacological evaluation of 2-[4-(aryl substituted) piperazin-1-yl] N, N-diphenylacetamides as potential antipsychotics.
    Kumar S, Wahi AK, Singh R.
    Eur J Med Chem; 2011 Sep 01; 46(9):4753-9. PubMed ID: 21824691
    [Abstract] [Full Text] [Related]

  • 5. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
    Campiani G, Butini S, Fattorusso C, Catalanotti B, Gemma S, Nacci V, Morelli E, Cagnotto A, Mereghetti I, Mennini T, Carli M, Minetti P, Di Cesare MA, Mastroianni D, Scafetta N, Galletti B, Stasi MA, Castorina M, Pacifici L, Vertechy M, Di Serio S, Ghirardi O, Tinti O, Carminati P.
    J Med Chem; 2004 Jan 01; 47(1):143-57. PubMed ID: 14695828
    [Abstract] [Full Text] [Related]

  • 6. Synthesis and SAR of (piperazin-1-yl-phenyl)-arylsulfonamides: a novel series of atypical antipsychotic agents.
    Park CM, Kim SY, Park WK, Choi JH, Seong CM.
    Bioorg Med Chem Lett; 2010 Sep 01; 20(17):5221-4. PubMed ID: 20655748
    [Abstract] [Full Text] [Related]

  • 7. Interactions of N-{[2-(4-phenyl-piperazin-1-yl)-ethyl]-phenyl}-2-aryl-2-yl-acetamides and 1-{[2-(4-phenyl-piperazin-1-yl)-ethyl]-phenyl}-3-aryl-2-yl-ureas with dopamine D2 and 5-hydroxytryptamine 5HT(1A) receptors.
    Sukalovic V, Ignjatovic D, Tovilovic G, Andric D, Shakib K, Kostic-Rajacic S, Soskic V.
    Bioorg Med Chem Lett; 2012 Jun 15; 22(12):3967-72. PubMed ID: 22607670
    [Abstract] [Full Text] [Related]

  • 8. Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT₁A/5-HT₂A/5-HT₇ and dopamine D₂/D₃ receptors.
    Zajdel P, Marciniec K, Maślankiewicz A, Grychowska K, Satała G, Duszyńska B, Lenda T, Siwek A, Nowak G, Partyka A, Wróbel D, Jastrzębska-Więsek M, Bojarski AJ, Wesołowska A, Pawłowski M.
    Eur J Med Chem; 2013 Feb 15; 60():42-50. PubMed ID: 23279866
    [Abstract] [Full Text] [Related]

  • 9. Design, synthesis, pharmacological evaluation and descriptor based similarities study of N,N-diphenyl-2-[4-(substituted phenyl)piperazin-1-yl]acetamides as potential antipsychotics.
    Dash RC, Bhosale SH, Shelke SM, Suryawanshi MR, Mahadik KR.
    Med Chem; 2012 Nov 15; 8(6):1069-75. PubMed ID: 22779792
    [Abstract] [Full Text] [Related]

  • 10. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
    Zazpe A, Artaiz I, Innerárity A, Del Olmo E, Castro E, Labeaga L, Pazos A, Orjales A.
    Neuropharmacology; 2006 Jul 15; 51(1):129-40. PubMed ID: 16643965
    [Abstract] [Full Text] [Related]

  • 11. Pharmacological evaluation of selected arylpiperazines with atypical antipsychotic potential.
    Tomić M, Kundaković M, Butorović B, Janać B, Andrić D, Roglić G, Ignjatović D, Kostić-Rajacić S.
    Bioorg Med Chem Lett; 2004 Aug 16; 14(16):4263-6. PubMed ID: 15261283
    [Abstract] [Full Text] [Related]

  • 12. Pharmacological evaluation of halogenated and non-halogenated arylpiperazin-1-yl-ethyl-benzimidazoles as D(2) and 5-HT(2A) receptor ligands.
    Tomić M, Vasković D, Tovilović G, Andrić D, Penjišević J, Kostić-Rajačić S.
    Arch Pharm (Weinheim); 2011 May 16; 344(5):287-91. PubMed ID: 21509803
    [Abstract] [Full Text] [Related]

  • 13. Structure-activity relationships of a series of substituted benzamides: potent D2/5-HT2 antagonists and 5-HT1a agonists as neuroleptic agents.
    Norman MH, Rigdon GC, Hall WR, Navas F.
    J Med Chem; 1996 Mar 01; 39(5):1172-88. PubMed ID: 8676355
    [Abstract] [Full Text] [Related]

  • 14. Quinoline- and isoquinoline-sulfonamide derivatives of LCAP as potent CNS multi-receptor-5-HT1A/5-HT2A/5-HT7 and D2/D3/D4-agents: the synthesis and pharmacological evaluation.
    Zajdel P, Marciniec K, Maślankiewicz A, Satała G, Duszyńska B, Bojarski AJ, Partyka A, Jastrzębska-Więsek M, Wróbel D, Wesołowska A, Pawłowski M.
    Bioorg Med Chem; 2012 Feb 15; 20(4):1545-56. PubMed ID: 22277589
    [Abstract] [Full Text] [Related]

  • 15. 3-substituted-1,2-benzisoxazoles: novel antipsychotic agents.
    Davis L, Effland RC, Klein JT, Dunn RW, Geyer HM, Petko WW.
    Drug Des Discov; 1992 Feb 15; 8(3):225-40. PubMed ID: 1356026
    [Abstract] [Full Text] [Related]

  • 16. Two new phenylpiperazines with atypical antipsychotic potential.
    Tomić M, Ignjatović D, Tovilović G, Andrić D, Roglić G, Kostić-Rajacić S.
    Bioorg Med Chem Lett; 2007 Nov 01; 17(21):5749-53. PubMed ID: 17870534
    [Abstract] [Full Text] [Related]

  • 17. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA.
    J Pharmacol Exp Ther; 1995 Oct 01; 275(1):101-13. PubMed ID: 7562537
    [Abstract] [Full Text] [Related]

  • 18. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
    Millan MJ, Svenningsson P, Ashby CR, Hill M, Egeland M, Dekeyne A, Brocco M, Di Cara B, Lejeune F, Thomasson N, Munoz C, Mocaër E, Crossman A, Cistarelli L, Girardon S, Iob L, Veiga S, Gobert A.
    J Pharmacol Exp Ther; 2008 Feb 01; 324(2):600-11. PubMed ID: 18024787
    [Abstract] [Full Text] [Related]

  • 19. Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes.
    Moran-Gates T, Massari C, Graulich A, Liégeois JF, Tarazi FI.
    J Neurosci Res; 2006 Aug 15; 84(3):675-82. PubMed ID: 16810690
    [Abstract] [Full Text] [Related]

  • 20. Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine.
    Rasmussen K, Benvenga MJ, Bymaster FP, Calligaro DO, Cohen IR, Falcone JF, Hemrick-Luecke SK, Martin FM, Moore NA, Nisenbaum LK, Schaus JM, Sundquist SJ, Tupper DE, Wiernicki TR, Nelson DL.
    J Pharmacol Exp Ther; 2005 Dec 15; 315(3):1265-77. PubMed ID: 16141369
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.